GCVI Summit 2018
Skip Content

14 November 2017

Entera enters IPO stage

Entera Bio, a large-molecule drug spinout of DNA Biomedical Solutions, intends to raise up to $50m when it goes public.

Author: Robert Lavine, News Editor

Entera Bio, an Israel-based large-molecule therapeutics developer spun out of drug-delivery technology provider DNA Biomedical Solutions, has filed to raise up to $50m in an initial public offering in the US.